GSK plc Overview
Pro stress-test →GSK plc is a British multinational pharmaceutical and biotechnology company. As of February 2026, it is the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. The company is strategically positioned across specialty medicines, vaccines, and immuno-oncology with accelerating pipeline momentum.
Strategic Profile
Pro stress-test →Sales grew 5% to £7.6 billion in Q1 2026, with growth driven by Specialty Medicines up 14% and vaccines contributing through strong Shingrix sales. Shingrix delivered record quarterly sales of more than £1 billion, up 20%, with European sales up 51% following uptake in national immunization programs. The company is aggressively prosecuting clinical development with multiple ADC (antibody-drug conjugate) programs and MASH therapeutics in phase III trials.
Competitive Landscape
Pro stress-test →GSK competes with Pfizer, Moderna, and Merck in vaccines; Eli Lilly, AstraZeneca, and Roche in oncology/specialty; Novo Nordisk and Boehringer Ingelheim in metabolic disease. Strongest competitive advantages lie in vaccines (Shingrix leading) and emerging ADC oncology portfolio. AstraZeneca is a primary UK-based pharmaceutical rival.
Industry Context
GSK plc operates in Pharmaceutical therapeutics and vaccines.
Key facts
Founded: 2000 · Headquarters: London, United Kingdom · Employees: Not available · Revenue: $42.4 billion (2025) · Market cap: $122.6 billion (February 2026)